Digital health for medication adherence among African Americans with hypertension - Abstract: Under the leadership of Patricia Weitzman, PhD, a multicultural, multidisciplinary team of clinicians and
researchers will collaborate to develop, formatively test, and evaluate the short-effectiveness of a digital provider
platform, called Memento.HTN, that is integrated with a patient SMS text system, and designed to support medication
adherence by African Americans with hypertension (HTN). HTN is more common and more destructive for African
Americans than for any other ethnic group. More than half of African American adults, about 15 million people, have
HTN. Furthermore, African Americans are 4 times less likely to adhere to HTN medications compared to their white
counterparts. Tailored approaches to reduce the racial gap in HTN morbidity and mortality, particularly those that support
medication adherence, are needed in primary care. Such approaches must overcome barriers due to cost or geographic
distance that can prevent African American patients from accessing adherence support. These approaches must also
overcome barriers to the delivery of adherence support that stem from healthcare systems themselves. Importantly, HTN is
one of most common co-morbidities in Covid19 hospitalizations, particularly for African Americans (CDC 2020).
Moreover, media coverage of a possible link between certain HTN meds, called RAAS inhibitors, and severe Covid19
outcomes may have alarmed HTN patients about the safety of their meds. As a result, the ACC (March, 2020) promptly
issued guidelines recommending all patients adhere to HTN meds during the pandemic unless advised by their physicians,
as there is no evidence of a link between HTN drugs and Covid19 severity. Thus, in the time of Covid19, supporting
medication adherence of African Americans with HTN is extremely urgent. Memento.HTN is innovative in three key
ways: 1) To our knowledge, it is the first-ever linked digital provider platform and patient SMS text system for HTN
medication adherence. 2) It is culturally-tailored for African Americans with HTN. 3) It has unique monitoring
functionality allowing providers to monitor individual patient adherence; support `new start' patients, who are at
increased risk for non-adherence; and track group adherence rates by drug class, pill format, and patient demographics,
which have never been included in any digital med adherence intervention. Thus, the Memento.HTN system greatly
simplifies and facilitates provider delivery of adherence support to patients, while enhancing their clinical therapeutics.
The provider platform sends patients interactive SMS-text pill reminders plus culturally-sensitive motivational,
educational, spiritual/stress-supportive, and customizable texts, along with texts targeting intentional non-adherence and
Covid19-related concerns. Texts go directly to patient cellphones (no mobile app needed), making the intervention
accessible to patients who do not possess smartphones. Importantly, Memento allows 2-way texting communication
between providers and patients, and automatically alerts providers when a patient has a clinically-significant pill lapse. We
believe Memento has significant commercial potential, as EHG has already developed plans for multiple digital
adherence interventions that will be marketed together to clinics serving large numbers of at-risk patients. This B2B
business model can generate large increases in revenues for customers, making our products attractive from both a
financial and health perspective.
